Biomarker evaluation in the phase III, placebo (P)-controlled, randomized BeTa trial of bevacizumab (B) and erlotinib (E) for patients (Pts) with advanced non-small cell lung cancer (NSCLC) after failure of standard 1st-line chemotherapy: correlation with treatment outcomes

被引：0
|
作者：
Herbst, Roy S. [1 ]
Stern, Howard [2 ]
Amler, Lukas [2 ]
Otterson, Gregory [3 ]
Lin, Ming [2 ]
O'Connor, Paula [2 ]
Hainsworth, John [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] Ohio State Univ, Columbus, OH 43210 USA
[4] Sarah Cannon Rsrch Inst, Nashville, TN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S323 / S323
页数：1
相关论文
共 50 条
  • [1] Biomarker evaluation in the Phase Ill, placebo (P)-controlled, randomized BeTa trial of bevacizumab (B) and erlotinib (E) for patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of standard 1st-line chemotherapy: correlation with treatment outcomes
    Herbst, Roy
    Stern, Howard
    Amler, Lukas
    Otterson, Gregory
    Lin, Ming
    O'Connor, Paula
    Hainsworth, John
    CANCER RESEARCH, 2009, 69
  • [2] Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo (P)-controlled, randomized BeTa trial for pts with advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy
    Otterson, G. A.
    O'Connor, P. G.
    Lin, M.
    Herbst, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Erlotinib as 1st-line therapy for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Merimsky, O.
    Cheng, C.
    Reck, M.
    Au, S.
    von Pawel, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)
    Stinchcombe, T. E.
    Janne, P. A.
    Wang, X.
    Bertino, E. M.
    Weiss, J. M.
    Bazhenova, L.
    Gu, L.
    Lau, C. J.
    Paweletz, C. P.
    Jaslowski, A. J.
    Gerstner, G. J.
    Baggstrom, M. Q.
    Graziano, S. L.
    Beardenlii, J.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2018, 29 : 522 - 522
  • [5] META-ANALYSIS OF RANDOMIZED PHASE II/III TRIALS ADDING BEVACIZUMAB TO PLATIN-BASED CHEMOTHERAPY AS 1ST-LINE TREATMENT IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Soria, J.
    Mauguen, A.
    Reck, M.
    Sandler, A.
    Nishio, M.
    Johnson, D.
    Besse, B.
    Pignon, J. P.
    ANNALS OF ONCOLOGY, 2010, 21 : 147 - 147
  • [6] TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for firstline chemotherapy
    Lee, S.
    Rudd, R.
    Khan, I.
    Upadhyay, S.
    Lewanski, C. R.
    Falk, S.
    Skailes, G.
    Partridge, R.
    Ngai, Y.
    Boshoff, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] TOPICAL: RANDOMIZED PHASE III TRIAL OF ERLOTINIB COMPARED WITH PLACEBO IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) UNSUITABLE FOR FIRST-LINE CHEMOTHERAPY: UPDATED ANALYSIS
    Lee, S.
    Upadhyay, S.
    Lewanski, C.
    Falk, S.
    Skailes, G.
    Marshall, E.
    Ngai, Y.
    Rudd, R.
    Hackshaw, A.
    Boshoff, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 421 - 421
  • [8] Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
    Johnson, B.
    Miller, V.
    Amler, L.
    Stern, H.
    Soh, C.
    O'Connor, P.
    Kabbinavar, F.
    EJC SUPPLEMENTS, 2009, 7 (03): : 5 - 6
  • [9] Phase II trial of sequenced bevacizumab and erlotinib with bevacizumab and chemotherapy for 1st line stage IIIB or IV non-small cell lung cancer (NSCLC)
    Cohen, E.
    Govindan, R.
    Kozloff, M.
    Mauer, A.
    Hoffman, P.
    Karrison, T.
    Stein, J.
    Szeto, L.
    Salgia, R.
    Vokes, E.
    EJC SUPPLEMENTS, 2006, 4 (12): : 42 - 43
  • [10] A phase III randomized placebo controlled NCCTG trial of carboxyaminoimidazole (CAI) in patients with advanced non-small cell lung cancer (NSCLC).
    Johnson, EA
    Marks, RS
    Mandrekar, S
    Hillman, S
    Mailliard, J
    Dentchev, T
    Reuter, N
    Jett, J
    Perez, EA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 634S - 634S
12345